SAB4200661

Monoclonal Anti-Dynamin 2 (DNM2) antibody produced in mouse

clone DYN2-11, purified from hybridoma cell culture

• Synonym(s): CMT2M, CMTDI1, CMTDIB, DI-CMTB, DYN2, DYNII, LCCS5, dynamin 2
• UNSPSC Code: 12352203
• NACRES: NA.41

Properties

• biological source: mouse
• Quality Level: 200
• antibody form: purified immunoglobulin
• antibody product type: primary antibodies
• clone: DYN2-11
• form: buffered aqueous solution
• mol wt: antigen ~98 kDa
• species reactivity: mouse, human, monkey, canine, rat
• concentration: ~1 mg/mL
• technique(s): immunoblotting: 2-4 μg/mL using using whole extract of HeLa cells.; immunofluorescence: 5-10 μg/mL using using HeLa cells.; immunoprecipitation (IP): 5-10 μg using using whole extract of HeLa cells.
• isotype: IgG1
• UniProt accession no.: P50570
• storage temp.: −20°C
• target post-translational modification: unmodified
• Gene Information: human ... DNM2(1785) ; mouse ... Dnm2(13430) ; rat ... Dnm2(25751)

Description

General description

Monoclonal Anti-Dynamin 2 (DNM2) (mouse IgG1 isotype) is derived from the hybridoma DYN2-11 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a synthetic peptide. Dynamin 2 (DNM2) also known as DYN2 belongs to the dynamins family of guanosine triphosphatase (GTPase) proteins.

The gene DNM2 (dynamin 2) is mapped to human chromosome 19p13. It is widely expressed. The protein has a catalytic amino-terminal GTPase domain, a middle domain, a pleckstrin homology domain (PH), a GTPase effector domain (GED) and a less conserved carboxyl-terminal proline/arginine rich domain (PRD).

Immunogen

synthetic peptide corresponding to a sequence at the N-terminal region of human DNM2 , conjugated to KLH

Application

Monoclonal Anti-Dynamin 2 (DNM2) antibody produced in mouse has been used in:

• immunoblotting
• immunoprecipitation
• immunofluorescence

Biochem/physiol Actions

DNM2 (dynamin 2) is a GTPase which is required for clathrin-mediated endocytosis. It is important for clathrin-coated pit maturation and clathrin-coated vesicle formation. DNM2 participates in neuronal morphology, axonal growth, centrosome cohesion, actin- and microtubular organization. Mutations in it are associated with Charcot-Marie-Tooth disease, centronuclear myopathy ADCNM (autosomal dominant centronuclear myopathy) and lethal congenital contractures syndrome type 5 (LCCS5). It is upregulated in prostate cancer.

Furthermore, DNM2 is upregulated in pancreatic cancer as it activates Ras-related C3 botulinum toxin substrate 1 (Rac1). It also promotes invasive cellular migration and lamellipod protrusion.

Physical form

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Safety Information

• Storage Class: 10 - Combustible liquids
• wgk_germany: WGK 1
• flash_point_f: Not applicable
• flash_point_c: Not applicable